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IntroductIon
Levothyroxine (L-T4) is the drug used worldwide in 
replacement therapy for patients with hypothyroidism, 
being the third most common medication dispensed in 
the United States in the last few years.1 L-T4 is also 
used as suppressive therapy after surgical removal of 
thyroid cancer2 and for treating patients with nodular 
goiter in order to arrest its growth, although this use 
is still debated.3
L-T4 was first isolated by Kendall in 1914 from 
animal-derived desiccated thyroid, which contains a 
combination of T4 and triiodothyronine (T3).4 Syn-
thetic L-T4 came into use for thyroid treatment in 
the 1950s and was widely adopted as the primary 
thyroid hormone replacement drug, replacing the 
natural desiccated thyroid that had been used during 
the previous 50-year period.5
Traditionally, L-T4 has been available in tablet form 
as a stable salt that contains sodium; approximately 60-
90 % of the dose is absorbed in the jejunum and ileum 
within 3 hours of ingestion.6 Absorption is maximal 
when it is taken on an empty stomach, demonstrating 
the importance of gastric acidity in the process. In 
fact, the acid gastric pH is essential to dissolve the 
tablet, removing sodium ion and converting L-T4 into 
a lipophilic molecule.7 Recently, novel formulations 
of L-T4, such as soft gel capsule and liquid form, 
have been made available. This review will focus 
on liquid L-T4 formulation and its potential benefit.
L-t4 tabLet therapy not aLways “easy”: 
causes of maLabsorptIon
Even though substitutive therapy with levothy-
roxine has been prescribed for more than 60 years 
and is considered an “easy” therapy, almost 50% of 
treated patients show abnormality of thyroid hormone 
profile after one year of treatment.8
There are many reasons to explain this fact. First 
of all, several conditions and diseases related to the 
gastrointestinal tract can influence the T4 tablet form 
pharmacokinetics. Drug dissolution and solubility is 
altered by an increase in gastric pH: the most common 
diseases altering the normal acid environment of the 
stomach are Helicobacter Pylori (HP) related gastri-
tis and atrophic gastritis of the body of the stomach 
due to hypo/achlorhydria and to the production of 
ammonia. This mechanism may alter the ionization 
status and the conformational characteristics of the 
thyroxine molecule and the efficiency of intestinal 
absorption of the hormone.9,10 Centanni et al have 
clearly demonstrated that patients with impaired acid 
secretion require an increased dose of thyroxine: the 
daily requirement of L-T4 was higher (by 22 to 34%) 
in patients with HP related gastritis, atrophic gastritis 
or both conditions.11
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Also the change in pH caused by PPI may be 
responsible for a reduced absorption of L-T4.12
To our knowledge, no data about the duration 
of the treatment with PPI necessary to inhibit L-T4 
absorption is available in the literature. on the other 
hand, it is known that rapid and consistent pH acid 
suppression is achieved on the first day of PPI treat-
ment; by this fact, we are led to believe that a few 
days on PPI treatment may be sufficient to reduce 
LT4 absorption.13
Another condition that requires an increased dose 
of tablet form L-T4 is celiac disease,14 including its 
“atypical” phenotype, characterized by little or no 
gastrointestinal symptoms. A recent study in celiac 
patients affected by hypothyroidism due to Hashimoto’s 
thyroiditis showed that if they were not correctly treated 
with a strict gluten-free diet, the therapeutic dose of 
T4 had to be increased by at least 50%.15 Given the 
prevalence of celiac disease in patients with thyroid 
autoimmunity (2-5%),16 it is recommended to always 
consider the occurrence of an occult gastrointestinal 
disorder in stable patients on chronic L-T4 therapy 
who suddenly exhibit a need for an increased dose. 
Lactose intolerance can also lead to an increased 
need for tablet form L-T4.17
There are two main reasons for this phenomenon. 
Undigested lactose draws water into the intestinal lu-
men and leads to bacterial fermentation; this causes 
osmosis and accelerates small intestinal transit, which 
reduces the contact time between lactose and residual 
enzymes and further decreases the hydrolysis of 
lactose.18 Moreover, many L-T4 formulation tablets 
contain lactose,19 thus further inducing the disorder 
with every drug administration.17 A recent study also 
found that a strict lactose-free diet in lactose intolerant 
patients led to a decrease in the TSH level without 
modifying L-T4 dosage.20
It is important to underline that drugs may influ-
ence L-T4 absorption.21
Last but not least, L-T4 is normally taken with 
breakfast. It is in well known fact that L-T4 assump-
tion ten minutes before drinking coffee also reduces 
its absorption (Table 1).8,21
Novel formulations of L-T4  
and their potential use
nowadays, novel levothyroxine formulations 
are available, namely, soft gel capsules and liquid 
form. The soft gel capsule contains L-T4 dissolved 
in glycerine in an outer gelatine shell.22 This structure 
provides protection from the variations of gastric pH 
and could also prevent binding to other substances 
in the intestinal lumen, such as coffee23 or other me-
dicaments (for example calcium or iron salts).21,24-27
The liquid form is composed only of L-T4 of 
variable concentrations, glycerine and ethanol. The 
most important advantage of an oral solution, com-
pared to the solid formulation, is the possibility of 
administration also in patients who are not able to 
swallow intact capsules or tablets.
Furthermore, as shown in a recent in vivo study, 
liquid L-T4 formulation also has a better absorption 
table 1. Endogenous and exogenous factors interfering with L-T4 absorption
foods Gastrointestinal diseases drugs
 9Food intake
 9Dietary fiber
 9Coffee 
 9Pompelmo Juice
 9Soya
 9H. pylori infection
 9Lactose intolerance
 9Celiac Disease
 9 Jejunoileal bypass or other bowel resection
 9 Inflammatory Bowel Disease
 9Chronic Autoimmune Gastritis 
 9Biliary cirrhosis 
 9Proton Pump Inhibitors
 9Ferrous sulfate
 9Calcium carbonate
 9Sucralfate
 9Sevelamer and other phosphate binders (e.g. Lanthanum carbonate)
 9Cholestyramine
 9Ciprofloxacin
 9Raloxifene
 9Aluminium hydroxide 
 9orlistat
Liquid levothyroxine and its potential use 3
rate. In fact, Yue et al have shown that L-T4 in liquid 
formulation peaks in blood faster than the tablet or 
the soft gel capsule (faster at maximum concentration 
(ng/mL) by an average of 30 min).28 The levothyrox-
ine rate and the extent of exposure are similar in the 
three types of formulations (tablets, soft gel capsule 
and liquid form), but the solution appears to reach 
the systemic circulation faster as dissolution is not 
needed before absorption starts.
These pharmacokinetic features could be respon-
sible for lower drug-food interactions.
proton pump InhIbItor  
and LevothyroxIne treatment
Because both LT4 and PPI are top prescribed drugs 
worldwide, it is not uncommon to encounter patients 
who take them concurrently.12 By inhibiting the H+/
K+ ATPase pump in the gastric parietal cells, PPIs 
increase gastric pH and therefore impair tablet LT4 
dissolution that occurs in the acid environment of 
the stomach, thereby reducing its absorption. When 
LT4 therapy fails to reach target serum TSH values, 
this is often addressed by increasing the daily dose 
of LT4. However, should the physician withdraw the 
interfering drug (or should the patient elect to do so) 
while maintaining the increased LT4 dose, there is 
then a real risk of iatrogenic hyperthyroidism. This 
situation is similar to LT4 over treatment occurring 
postpartum if the LT4 dose has not been decreased 
back to the pre-pregnancy dose. LT4 over treatment 
is particularly undesirable in older patients, in whom 
the risk of arrhythmias or fracture is higher.29 In addi-
tion, the necessity of monitoring serum TSH regularly 
causes serum TSH assays to be repeated frequently, 
a practice that raises health costs.
Recent studies by Vita R et al have clearly dem-
onstrated that tablet LT4 malabsorption induced by 
PPI are resolved effectively with both the soft gel 
capsule and the liquid solution.31,32
“Good breakfast for a Good mornInG”
Coffee impairs tablet L-T4 absorption by binding 
L-T4.23 Furthermore, studies on stability, carried out 
with tablet formulations, have shown that sodium L-T4 
is rapidly degraded at 60° C.33,34 In a well researched 
study, Bernareggi et al performed in vitro recovery 
tests on known concentrations of T4 in the presence 
of saline, freshly brewed espresso coffee or known 
T4 sequestrants such as dietary fibers from bran or 
drugs like sucralfate.23 While in saline T4 recovery 
was complete, after dilution of T4 solution in coffee 
it ranged from 56 to 80%. The T4 recovery was even 
lower in suspensions of dietary fibers and sucralfate 
(ranging from 17% to 47%). These findings may be 
due to T4 sequestration or T4 degradation. Conversely, 
stability of levothyroxine liquid formulation in milk, 
tea, coffee with milk warmed to 50° C and orange 
juice at room temperature was demonstrated at up 
to 20 minutes of incubation, without evidence of T4 
degradation in different types of matrices.35
Recently, Cappelli et al. highlighted the same 
results in a small group of 54 patients who wrongly 
consumed oral liquid L-T4 prior to breakfast within 
the very first few minutes or also at breakfast in their 
coffee. A comparable thyroid hormonal profile was 
obtained in patients who wrongly took L-T4 liquid 
formulation compared to controls who consumed it 
30 min before breakfast.36
The hypothesis is that the presence of alcohol in 
the liquid formulation could play a key role in the 
absorption of T4. Indeed, oral mucosal drug delivery 
is known as an alternative method for systematic drug 
delivery offering several advantages.37 Because the 
oral mucosa is highly vascularized, drugs that are 
absorbed through the oral mucosa enter the systemic 
circulation directly, bypassing the gastrointestinal 
tract.37 Furthermore, it is conceivable that liquid L-T4 
formulation could also be better absorbed because it 
circumvents the pH related dissolution phase.
L-t4 therapy after barIatrIc surGery
These considerations are also useful in patients 
who undergo bariatric surgery.
Usually, once ingested, only a small fraction of 
levothyroxine tablet form is assimilated in the stom-
ach, being mainly absorbed in the small intestine, in 
particular in the duodenum and jejunum;6 this fact 
explains why patients suffering from short bowel 
syndrome (following bowel resection) require a 
higher dosage of levothyroxine.38,39 The liquid L-T4 
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formulation may minimize this problem. In fact, a 
recent study has shown a reversible normalization of 
serum TSH levels in patients submitted to bariatric 
surgery (in particular to Roux-en-Y gastric bypass), 
after switching from the tablet form of L-T4 to oral 
liquid formulation. The observation that the switch 
from a tablet to oral formulation was effective in nor-
malizing serum TSH levels and that switching back 
to the tablet formulation led to an increase of TSH 
levels in our patients after bariatric surgery leads us 
to believe that the absorption of T4 is greater when 
an oral liquid formulation is used.40 Furthermore, it 
is conceivable that liquid L-T4 formulations could 
also circumvent the pH alteration resulting from a 
gastric bypass.
L-t4 and enteraL nutrItIon
Working on the basis of the possible amelioration 
of liquid L-T4 therapy also on a non-empty stomach, 
we recently analyzed the thyroid hormonal profile 
in patients with an enteral feeding tube after total 
laryngectomy for laryngeal cancers. Since total thy-
roidectomy is a common surgical practice in patients 
submitted to this kind of surgery,41 these patients also 
started L-T4 replacement therapy after surgery. The 
majority of clinicians suggest that enteral feedings 
should be carried out 1-2 hours prior to and after 
L-T4 administration despite the lack of data sup-
porting continuous enteral nutrition.42 We compared 
the thyroid hormonal profile in 20 patients submitted 
to L-T4 treatment in tablets or in liquid formulation 
with an enteral feeding tube and we found no differ-
ence of TSH, fT4 and fT3 between patients treated 
with tablets interrupting enteral continuous nutrition 
for 30 min before and after L-T4 administration 
and patients treated with liquid formulation placed 
into the nasoenteric tube immediately. Furthermore, 
the nurses preferred the use of liquid formulations 
to crushed tablets, since it reduced the time spent 
preparing and administering the medication. Moreo-
ver, crushing tablets before administering them may 
change and alter the pharmacokinetics and pharma-
cological properties.43 our data showed that liquid 
L-T4 formulation can be administered through a 
feeding tube with no need for an empty stomach.44 
These data reinforces our hypothesis that oral L-T4 
liquid formulation could be very helpful in coping 
with the problem of L-T4 malabsorption caused by 
food when using traditional tablet formulations, as 
has also been recently demonstrated both in adults 
and in children.45,46
LIquId formuLatIon In paedIatrIc 
patIents
Giving levothyroxine to infants can be a chal-
lenge when it is prescribed in tablet form which often 
needs to be crushed. Use of liquid L-T4 formulation 
has been investigated for the first time in paediatric 
patients with congenital hypothyroidism. This is the 
most frequent congenital endocrine disorder and 
early treatment enables normal mental and physical 
development. However, some children, despite early 
diagnosis and therapy, show abnormal mental devel-
opment and poor long-term outcome. There are many 
reasons for this phenomenon such as the age at the start 
of the therapy, socio-economic factors, the parents’ 
compliance and the initial dosage of L-thyroxine.47 
An initial daily dose of 10-15 mcg/kg, according to 
prenatal severity of congenital hypothyroidism, has 
been recommended in the US and Europe.48,49
Peroni et al compared L-T4 liquid and tablet for-
mulations in the initial treatment of congenital hypo-
thyroidism, demonstrating that normalization of TSH 
is achieved in significantly more patients taking the 
liquid formulation than those on the tablet formulation; 
moreover, infants in treatment with liquid formulation 
had significantly lower TSH values.46 Cassio et al 
also showed an incomplete bioequivalence between 
drops and tablets. L-T4 liquid formulation normal-
ized TSH in significantly more patients affected by 
severe congenital hypothyroidism; no significant 
differences were reported in patients with moderate/
mild hypothyroidism.50
better stabILIty of LIquId formuLatIon 
Several studies have compared the effectiveness 
of liquid L-T4 formulation over tablet form in keep-
ing the patient euthyroid. negro et al. demonstrated 
that liquid formulation, as compared to the tablet, 
resulted in a significantly higher number of hypothy-
roid patients who maintained the euthyroid state in 
12 months of follow-up, with a significant reduction 
of variability in TSH values.51 our recent retrospec-
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concLusIon
Many studies suggest for the first time that liquid 
L-T4 formulation could reduce the problem of L-T4 
malabsorption encountered when using traditional 
tablet formulations. This could ameliorate the com-
pliance of ‘thyroid’ patients, while simultaneously 
reducing health expenditure. The potential use of 
new L-T4 forms in a wide range of malabsorption 
conditions makes this formulation very attractive for 
both physicians and patients.
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